VOLUME 38 1991

SUBJECT INDEX

AB mice, 471
Acetylcholine, 115, 227, 501, 723, 731, 921
Acetylcholinesterase, 93
Acetyltransferase, 813
ACh release, 441
Acomys cahirinus, 913
Acoustic startle reflex, 769
Activity, 485
Acute dependence, 711
Adenosine receptors, 1
Adenosine uptake sites, 1
Adenylate cyclase, 555
Adrenalectomy, 593
Adrenaline, 13, 299
α_1-Adrenoceptor, 353
α-2-Adrenoceptor, 287
Affective disorders, 227, 695
Afterdischarge, 669
Aggression, 485, 587, 639
Aggressiveness, 471
Aging, 861
Alcohol-ethyl, 639
Alcohol intake, 881
Alpha-1 adrenergic receptors, 905
Alprenolol, 353
Alzheimer's disease, 141, 921
Ambient temperature, 339
2-Amino-1,2-dihydronaphthalene (ADN), 581
2-Aminoindan, 581
2-Aminotetralin (AT), 581
Ambulatory activity, 781
Amphetamine, 365, 375, 467, 927
(+)-Amphetamine, 581
d-Amphetamine, 417, 633
Amygdaloid kindling, 669
Analgesia, 155, 185, 401, 485, 561, 681, 795, 853
Analgesic, 21
Analgesic agents, 909
Angiotensin II, 913
Angiotensin II-induced drinking, 837
Animal model, 141, 889
Animal model of depression, 191
Anorexia, 459, 905
Antagonism, 479
Anterograde amnesia, 651
Antidepressants, 621
Antihypertensive agents—adverse side-effects, 55
Antinociception, 287, 753
Antiopiate, 273
Antiseizure efficacy, 665
Anxiety, 63, 99, 519, 651, 889
Anxiety drugs, 769
Anxiety reduction after ejaculation, 807
Anxiolytics, 43
Apomorphine, 309, 321, 463, 869, 917
Appetitive conditioning, 109
Approach behavior, 191
Arousal, 333, 723
Arrhythmias, 601
Arterial blood pressure, 913
ASU 1–7 eel calcitonin, 561
Atipamezole, 287
Atmospheric pressure, 639
Atropine, 747
Autoradiography, 621
Aversive stimuli, 401, 795
Avoidance behavior, 191

BC-264, 545
BC (3016), 401
BDZ receptor ligands, 13
Behavior, 155, 539, 639, 817
Behavior genetics, 893
Behavioral deficit, 441, 795
Behavioral economics, 715
Behavioral pharmacology, 527
Behavioral teratology, 739
Behavioral toxicology, 527
Benoxathian, 905
Benzodiazepine and fixed interval behavior, 823
Benzodiazepine and spontaneous activity, 823
Benzodiazepine inverse agonist, 763
Benzodiazepine receptor, 99
Benzodiazepines, 43, 781, 889
Beta-funaltrexamine, 49
Bicuculline, 593
Bilateral transection, 931
Binding, 231
Blink rate, 869
Blood-brain barrier, 155, 327
Blood ethanol concentration, 699
Blood pressure, 55, 601, 843
Body temperature, 29, 253
Body weight, 495
Brain ethanol, 29
Brain injury, 327
Brain lesions, 869
Brain serotonin, 775
Brain-stimulation reward, 645
Bright light, 227, 695
2-Bromolisuride, 321
BUBU, 155
Burying behavior, 63, 371, 807
Buspirone, 299, 611

C57BL/6J mice, 177, 897
Caffeine, 333, 513
Calcium channel blocking agents, 55
Canine narcolepsy, 1
Carbachol, 115
Carbamate, 527
Carbohydrate intake, 177
β-Carbolines, 519
5-Carboxamidotryptamine, 459
Cardiotoxicity, 601
Cardiovascular, 333
Cardiovascular function, 843
Cat, 287
Catalepsy, 105, 673, 875
Catecholamines, 345, 677
Catecholamines, plasma, 843
Cathinone, 7
Caudate nuclei, 739
CCK, 479
CCK antagonists, 207
CCK-B receptors, 545
Cellular tolerance, 29
Central nervous system, 147
Cerebrospinal fluid, 677
CGS 10746B, 7
Chicken, 247
Chlordiazepoxide, 13, 43, 299, 375, 433
p-Chloroamphetamine, 135
Choline, 723
Choline acetyltransferase, 861
Cholinergic, 227, 243, 501
Cholinergic muscarinic binding, 861
Cholinergic supersensitivity, 105
Cholinergic systems, 527
Cholinesterase inhibitor, 549
Chronic, 495
Chronic administration, 611
Chronic opioid agonists and antagonists, 485
Chronic variable stress, 125
Circadian rhythms, 253
Cigarette smoking, 333, 417
Circling training, 739
Climbing, 463
Clonidine, 177
Clorgyline, 677
Cocaine, 267, 287, 353, 411, 467, 601, 893, 897, 927
Coffee, 333
Cognition, 169
Colchicine, 141
Cold challenge, 253
Cold exposure, 837
Cold-induced hypertension, 837
Cold stress, 813
Color discrimination, 55, 77
Compensatory tracking, 527
Computed tomography, 327
Conditioned avoidance responses, 705
Conditioned place preference, 7, 539
Conditioned position responding, 77
Conditioned suppression, 309
Conditioned taste aversion, 267, 375, 479
Conditioning, 375
Consolidation, 651
Corticosterone, 13, 299
Cross-dependence, 433
Cross-tolerance, 195, 427, 433
CSF, 677
CY 208-243, 259
Cyclo(His-Pro), 359, 365
d-Cycloserine, 665

D_1, 243
D_2, 243
D_2 agonist, 147
D1 receptor, 215, 259
D2 receptor, 215
DAGO, 155, 185
Defeat, 485
Delayed matching-to-sample, 77
Delta and mu opioid receptors, 185
Delta opioid agonist, 155
Dependence, 433
Depression, 315, 695
Desipramine, 621
Dexfenfluramine, 495, 775
5,7-DHT, 807
Diazepam, 63, 389, 471, 651
Diet selection, 495

5,7-Dihydroxytryptamine, 447
Discriminative stimulus, 407
Displacement activities, 889
Dispositional tolerance, 823
Diurnal activity, 633
Dizocilpine, 673
DMCM, 13, 99
DOCA-salt hypertension, 55
DOI, 353
Domestic fowl, 49, 587
Dominance, 587
Dopamine, 7, 69, 147, 215, 505, 539, 705, 789, 869, 917
Dopamine antagonist, 321
Dopamine D-2 receptors, 131
Dopamine receptors, 829
Dopamine sensitivity, 105
Dorsal raphe nucleus, 223
Dose-effect, 141
DPDPE, 185
Drinking, 253, 459, 913
Drug dependence, 389
Drug discrimination, 7, 99, 211, 407, 519, 539, 581, 763
Drug effects, 77
Drug regimen, 927
Drug seeking, 389
DSP4, 807

Early exposure, 575
ED_{50}, 673
EEG, 293
Ejaculation, 371
Eltoprazine (DU 28853), 447, 759
Endorphin, 909
β-Endorphin, 795
Enkephalinase inhibitor, 21
Enkephalins, 155
Epilepsy, 163
Epileptic spiking, 327
Escape deficit, 125
Eseroline, 747
Ethanol, 29, 293, 389, 427, 433, 639, 665, 699, 763
Ethanol initiation, 575
Ethanol reinforcement, 575
Ethopharmacology, 889
Ethyl-beta-carboline-3-carboxylate, 63
(+)-α-Ethylphenethylamine, 581
Etorphine, 475
Evaporative water loss, 339
Experience of defeat, 315
Exploration, 759

Fat, 681
Feed restriction, 587
Feeding, 379, 495
Fenfluramine, 365
Fentanyl, 475
FG 7142, 99, 519
Fimbria fornix, 931
Fixed ratio, 897
Fixed-ratio (FR) liquid-reinforced behavior, 699
Fixed-ratio responding, 747
Fixed-ratio schedule, 411
Flumazenil, 13
2-(Fluorohydroxyphenyl)ethylamines, 131
Fluoxetine, 495
Flurazepam, 659
Flurazepam, behavioral tolerance, 823
Flurazepam elimination half-life, 823
Flurazepam pharmacokinetics, rat, 823

Food adaptation, 85
Food intake, 223, 235, 359, 379, 417, 605, 775
Footshock, 69
Foot shock-induced analgesia, 561
Formalin test, 247
Forskolin, 753
Frontal cortex, 93, 723
FSL and FRL rats, 105

GABA, 385, 659, 781, 801
GABA antagonist (RU 5135), 327
$GABA_A$ receptor, 235
GABA receptors, 829
Gap inhibition, 769
Gender differences, 253
Genetic obesity, 177
Ginkgo biloba, 109
Glutamate, 385
G-proteins, 1

Halazepam dependence, 561
Halazepam metabolism, 561
Halazepam pharmacokinetics, 561
Haloperidol, 471, 633, 645, 739, 869, 875
Hamster, 711
HDL-C, 813
Head-twitch, 353
Heart rate, 339, 843
Heat challenge, 253
Hematocrit, 913
Hematuria, 689
Hexobarbital, 471
5-HIAA, 677
Hippocampus, 93, 621, 705, 723, 801, 861
Hot-plate, 185
HPLC-EC, 135
$5\text{-}HT_{1A}$, 691
$5\text{-}HT_2$, 691
5-HT agonists, 495
5-HT behavioral syndrome, 555
5-HT receptors, 201
$5\text{-}HT_1$-like receptors, 459
$5\text{-}HT_1$ receptors, 447
$5\text{-}HT_{1A}$ activity, 407
$5\text{-}HT_{1A}$ receptor, 353, 555
$5\text{-}HT_{1A}$ receptor agonist, 441
$5\text{-}HT_2$ receptor, 353
$5\text{-}HT_3$ receptor antagonist, 169
5-HTP, 201
Human, 417
Hunger, 379
HVA, 677
6-Hydroxydopamine, 215
5-Hydroxytryptamine, 459
5-Hydroxytryptamine (5-HT) or serotonin, 191
5-Hydroxytryptophan (5-HTP), 191
Hyperalgesia, 247
Hyperbaric, 639
Hyperbaric pressure, 219
Hyperthermia, 339
Hypertonic NaCl, 913
Hypothalamus, 379
Hypothermia, 235, 339, 651

ICI-154,129, 485
ICS 205-930, 353, 605
Imipramine, 93, 125, 407, 621
Impotence, 917
In vitro binding, 155, 621
In vivo binding, 155, 621
Incremental repeated acquisition, 77

Individual differences, 467
Indole-2-carboxyiic acid, 665
Inhalation, 699
Insecticide, 235
Insulin, 533
Intracerebroventricular, 185
Intracerebroventricular infusion, 379
Intranigral infusion, 617
Intravenous administration, 155
Inverse agonist, 99, 519
Iodoaminoindan, 135
p-Iodoamphetamine, 135
3-Isobutyl-1-methylxanthine, 753
Isoproterenol HCl, 913

Jaw-opening reflex, 287

Kainic acid, 689
Kappa receptors, 401
Ketamine, 211, 869
Ketanserin, 605
Kindling, 163

L-365,260, 207
Latent inhibition, 309
Lateral ventricle, 705
LD_{50}, 673
Learned helplessness, 93
Learned tolerance, 29
Learning, 77, 231, 651
Learning and memory, 731
Lecithin:cholesterol, 813
Lethality, 339, 673, 893
Lever press, 109
Levorphanol, 485
LHRH, 705
Licking, 463
Lindane, 235
Lisuride, 321
Lithium, 93, 375, 533
Locomotion, 155, 441
Locomotor activity, 265, 321, 385, 467, 723, 829, 875
Locomotor/exploratory activity, 817
Locus coeruleus, 621
Long latency event-related potentials, 789
Long-term potentiation, 163

Macronutrient selection, 177
Male and female rats, 795
Male sexual behavior, 201
MAOI, 677
Marble burying, 63
Marmoset, 147, 169
Maze, 759
McN-A-343, 115
MDMA, 345, 539
Meal-feeding, 177
Mechanisms of anesthesia, 639
Mechanisms of intoxication, 639
Medetomidine, 287
Median raphe nucleus, 223
Memory, 77, 109, 141, 243, 651
Memory search, 281
5-MeODMT, 201
Metabolic rate, 339
Metabolism, 345
Metaphit, 231
Methohexital, 411
N-Methyl-D-aspartate, 673
5,6-Methylenedioxy-2-aminoindan (MDAI), 581
Methylenedioxyamphetamines, 505

α-Methylepinine, 345
N′-Methylnicotinium iodide, 843
Methysergide, 605
Metoclopramide, 917
MHPG, 677
Mice, 109, 485, 593, 639, 763, 817
Microdialysis, 723
Microtubule, 141
Midazolam, 611
MK-329, 207
MK-801, 163, 211, 231, 665, 673
M. nemestrina, 677
Monkeys, 77, 677, 869
Morphinan, 401
Morphine, 37, 49, 77, 185, 195, 247, 273, 673, 681, 711, 753, 817, 853
Morphine dependence, 479
Morris water maze, 651, 931
Mortality, 689
Motivation, 77, 417
Motor activity, 339, 471, 633
Motor behavior, 55, 259
Motor execution, 781
Mouse, 259
MPTP, 147, 869
Mu, delta, kappa opioids, 485
Multiple FR-TO schedule, 549
Mu opioid agonist, 155
Mu receptors, 401
Muscarinic, 227, 243
Muscarinic receptors, 695
Muscarinic subtypes, 115
Mus musculus, 177
Myoclonus, 235

N. accumbens, 705
Naloxone, 37, 43, 85, 247, 265, 371, 711, 747
Naloxone hypophagia, 605
Naltrexone, 485, 775, 853
Naltrindole, 49, 185
NAN-190, 407
Narcotic antagonists, 247
Narcotic drugs, 247
Neurotoxicity, 505
Neurokinin receptors, 223
Neurokinins, 223
Neuroleptics, 645
Neuromodulation, 365
Neuropeptide Y, 379
Neuropeptide Y_{1-27}, 379
Neurotensin, 463, 569
Neurotoxicity, 135, 345, 505, 539
Neurotoxin, 689
NH_2-senktide, 881
Nicotine, 281, 333, 501, 875, 921
(+)-Nicotine, 843
(−)-Nicotine, 843
Nimodipine, 665
Nitrazepam, 265
NMDA, 385
NMDA receptor, 665
NMDA receptor antagonist, 163
Nociception, 49, 247, 287, 401
Nondeprived subjects, 223
Nonhuman primates, 677, 889
Nonhuman primates—baboons, 55
Noradrenaline, 13, 299, 807
α-Noradrenergic, 177
Nor-binaltorphimine, 49
Norepinephrine, 69
Novel object, 759
Novelty, 467
Nucleus accumbens, 829
Nucleus basalis magnocellularis, 731

Obesity, 533
Object discrimination reversal, 169
ob/ob, 177
Obsessive-compulsive disorder, 63
Occasional smokers, 281
Offensive aggression, 447
8-OH-DPAT, 407
Ondansetron, 169
Ontogeny of ingestion, 207
Open field, 759
Operant behavior, 77, 195
Operant conditioning, 141, 739
Operant performance, 549
Opiate, 49, 247, 475, 673, 909
Opiates and drinking, 85
Opiates and feeding, 85
Opioid, 247, 673
Opioid antagonist, 185, 801
Opioid peptides, 195, 775, 801
Opioid receptors, 49, 155, 195, 853
Oral dyskinesia, 215
Oral movements, 617
Org2766, 931
Organophosphate, 527
Osmotic minipump, 677
Oxotremorine-M, 115
Oxytocin, 273

Pain, 49, 247
Palatability, 375
Pancreas, 909
Paralytic effects, 475
Paraventricular nucleus, 905
Parkinson's disease, 147
Passive avoidance, 231, 931
PCP, 231
PCPA, 253
Penile erection, 131
Pentobarbital, 427
Pentylenetetrazol, 471
Peptides, 379
Perforant path, 801
Performance, 417
Peripheral benzodiazepine, 235
Peripheral serotonergic mechanisms, 459
Pertussis toxin, 561, 853
Phencyclidine, 211
Phenoxybenzamine, 689
Phenylpropanolamine, 905
PHNO, 869
Phosphoinositide turnover, 861
Physostigmine, 115
Picrotoxin, 235
Pigeon, 407, 611
Piloerection, 339
Pirenzepine, 115
Place conditioning, 513, 645
Plasma renin activity, 837
Plasma β-endorphin, 219
Polyethylene glycol, 913
Position discrimination, 77
Postsynaptic serotonin receptors, 191
Power spectra, 293
Precipitated withdrawal, 479
Preference test, 37
Prefrontal cortex, 645
Preoptic area, 385
Presynaptic receptor, 441
Principal Component Analysis (PCA), 817
Progressive ratio, 77
Prolyl-leucyl-glycinamide, 273
Psychopharmacology, 375
Psychosis, 927
PTZ, 99
Pyridostigmine, 549

Quantitative autoradiography, 447
Quinpirole, 309

Radial-arm maze, 243
Rapid, 427
Rat, 7, 13, 37, 43, 93, 99, 201, 253, 267, 299, 309, 321, 427, 447, 467, 519, 533, 539, 545, 575, 617, 669, 685, 699, 731, 769, 893, 921, 927
Receptor binding, 691
Receptor interactions, 829
Receptor occupancy, 155
Receptors, 227, 501
Receptor turnover, 691
Recovery, 931
Reinforcement, 715
Renin-angiotensin system, 837
Renovascular hypertension, 55
Repeated ECS, 691
Reserpine, 259
Resident-intruder, 447
Residential laboratory, 417
Restraint, 185
Retention, 651
Rhesus monkeys, 527
Ritanserin, 605
Ro 5-4864, 235
Ro15-1788, 433
Ro 15-4513, 763
Ro 20-1724, 753
Rodents, 147
Rolipram, 753
Rotation, 659
Route of administration, 267, 601
RU 24969, 495

Saccharin, 681
Saccharin concentrations, 37
Salivation, 339
Satiety mechanism, 379
SCH 32615, 21
Schedule-controlled behavior, 611, 747
Schedule-induced polydipsia, 85
Scopolamine, 115, 243, 467, 723
Scratching, 889
Scuba divers, 219
Seasonal affective disorder, 227
Second-order schedule, 411
Sedation, 651
Seizures, 235, 593
Self-administration, 411, 897
Self-stimulation, 645, 699
Senktide, 223, 617
Sensitization, 467
Sensorimotor reactivity, 769
Sensory contact model, 315
Septide, 617
Serotonergic supersensitivity, 447
Serotonin, 69, 135, 365, 459, 505, 539, 731, 789, 807
Serotonin agonist, 321, 459
Serotonin analogs, 459
Serotonin antagonists, 459
Serotonin depletion, 253
Serotonin receptors, 459
Serotonin receptor subtypes, 605
Sex, 533

Sexual behavior, 115, 273, 781
Shock stress, 93
Shuttle-box, 125
Signalled punishment, 43
SKF 38393, 215, 309
Skin temperature, 339
Sleep, 545
Sleep-wake cycle, 293
Smoking, 715
Sniffing, 463
Social attraction, 759
Social behavior, 389, 417
Social conflict, 485
Social dominance, 389
Social isolation, 389
Spatial learning, 931
Spiny mouse, 913
Spiperone, 215
Spontaneous alternation, 441
Spontaneous motor activity, 705
Squirrel monkey, 411, 633
Stereotypy, 105, 463
Stimulant, 339, 581
Stimulus properties of drugs, 99, 519, 539
Strain, 69
Stress, 185, 299, 501
Stretching and yawning, 131
Striatum, 93, 705, 723
Structure-activity relationships, 505
Subarachnoid catheterization, 685
Subjective effects, 417
Subjective ratings, 281
Submissive male, 315
Subsensitivity, 659
Substantia innominata, 385
Substantia nigra, 617
Substantia nigra pars reticulata, 659
Sucrose, 681
Sudden death, 601
Sulpiride, 533, 869
Supersensitivity, 853
Substitutability, 715
Synaptosomes, 505

Tachykinin analogues, 617
Tachykinins, 881
Tail-flick, 185, 681
Tardive dyskinesia, 617
Taste aversion, 513
Taste reactivity test, 375
Telemetry, 339
Temperature, 105
Temperature regulation, 235
Temporal response differentiation, 77
Test battery, 77
Test/treatment interaction, 817
THBC, 519
Theory of depression, 191
Thiazide diuretics, 55
THIP, 659
Thyrotropin-releasing hormone, 359
Time-course, 747
Time perception, 77
Tobacco, 921
Tolerance, 265, 427, 433, 467, 485, 699, 843
Tooth pulp, 287
Toxicity, 893
Toxicokinetics, 235
TRH, 669
Tritiated probe, 155
Tryptophan, 587
Tyrosine-prolyl-leucyl-glycinamide, 273

U-50,488, 485
Ultrasonic motion detector, 633
Upregulation, 853

Verapamil, 55
Vitamin A, 739
Voltage-sensitive calcium channels, 665

Water deprivation, 913
Water intake, 223, 379, 913
Wet dog shakes, 801
Withdrawal, 485, 711
Withdrawal signs, 433
Withdrawal symptoms, 281

Yawning, 917
YM-14673, 669
Yohimbine, 63, 353

Zimelidine, 63

AUTHOR INDEX

Abbott, B., 259
Adams, J. U., 195
Afani, A., 705
Agmo, A., 781
Ahlenius, S., 201
Akarid, K., 37
Akil, H., 673
Alex, P. K., 699
Algeri, S., 931
Ali, S. F., 861
Alkana, R. L., 639
Alleva, E., 817
Andrea, M. E., 125
Anisman, H., 69
Aprison, M. H., 191
Azcurra, J. M., 739

Baamonde, A., 155
Babbini, M., 639
Bakshtanovskaya, I. V., 315
Bao, K., 763
Baptista, T., 533
Barnes, M. I., 801
Barrett, J. E., 407
Bar-Ziv, J., 327
Becker, A., 471
Becker, H. C., 763
Beczkowska, I. W., 605
Behm, F. M., 333
Belleau, B., 401
Beninger, R. J., 513
Bensimon, G., 141
Benvenga, M. J., 211
Berninsone, P. M., 739
Biegen, M. T., 681
Blick, D. W., 527
Bodnar, R. J., 605
Bosy, T. Z., 593
Bowers, B. J., 593
Bowersox, S., 1
Brase, D. A., 219
Breese, G. R., 621
Brewster, W. K., 345
Brockwell, N. T., 513
Brown, G. C., 527
Brusés, J. L., 739
Bulik, C. M., 715
Burguera, J. L., 533
Burguera, M., 533

Cada, D. A., 115
Caggiula, A. R., 715
Calcagnetti, D. J., 185
Chan, A. W. K., 433
Chang, S.-C. J. L., 853
Chaplin, R. I., 789
Chermat, R., 141
Chiarotti, F., 817
Chipkin, R. E., 21
Chodera, A., 265
Christensen, A. V., 93
Claudi, F., 131
Coffin, V. L., 21
Coghill, R. C., 475
Cohen, Y., 775
Cooley, R. K., 689
Copeland, R. L., Jr., 293, 699
Costall, B., 147, 169
Cox, M., 677
Crocker, A. D., 105
Currie, P. J., 177
Czech, D. A., 913

Damsma, G., 723
Daniel, S. S., 763
Danysz, W., 231
Darmani, N. A., 353
Davies, B. T., 905
Day, J., 723
De Boer, S. F., 13, 299
DeBold, J. F., 639
De Caro, G., 881
de Kloet, E. R., 447
Delay-Goyet, P., 155
Del Vecchio, R. A., 211
Dement, W., 1
de Saint Hilaire, Z., 545
Deutsch, S. I., 665
Dewey, W. L., 219
Diaz-Veliz, G., 705
Dilsaver, S. C., 227, 501, 695
Dohanich, G. P., 115
Dolan, S., 823
Domeney, A. M., 147, 169
Dong, L., 843
Douglass, L. W., 587
Dreher, J., 829
Drumheller, A., 463
Drummer, H. L., 235
Dulinski, J., 691
Duncan, G. E., 621
Duvauchelle, C. L., 645

Eastman, N. W., 219
Eden, R. J., 147
Ehlers, C. L., 789
Eikelboom, R., 513
Ellison, G., 927
Elmer, G. I., 897
Emerich, D. F., 875
Epstein, L. H., 715
Eshel, G., 829
Ettenberg, A., 645

Facchinetti, F., 795
Falk, J. L., 823
Farabollini, F., 795
Fassberg, J. B., 621
Feldon, J., 309
Fernández, H., 781
Fernández-Guasti, A., 371, 807
Ferrari, C. M., 267
Ferrari, F., 131
Fibiger, H. C., 723
Fink, H., 321
Finn, D. A., 639
Fischman, M. W., 417
Flemmer, D. D., 227
Foltin, R. W., 417
Fregly, M. J., 837
Frenk, H., 475
Fujimoto, K., 163

Gacel, G., 155
Gagne, M. A., 463
Garrick, N., 677
Gennaro, M., 677
Geoffroy, M., 93
George, F. R., 893, 897
Gerrard, P. A., 147, 169
Geter, B., 85
Ghosh, T. K., 293, 699
Gibbs, J., 207
Gibson, B. M., 759
Giordano, J., 49
Giroux, M. L., 695

Gispen, W. H., 931
Glennon, R. A., 353
Goldberg, S. R., 411, 897
Gomez, R. A., 125
Gordon, C. J., 339
Gori, E., 569
Gorzalka, B. B., 273
Grecksch, G., 471
Guan, X.-M., 505
Gunne, L., 617

Hack, S., 281
Hamdi, A., 215
Handley, S. L., 63
Hartgraves, S. L., 527
Harvey, C. A., 147
Hawkins, M., 1
Heaton, J. P. W., 917
Heinsbroek, R. P. W., 795
Hernandez, L., 533
Heyne, A., 389
Hienz, R. D., 55
Hijzen, T. H., 769
Hillman, D. E., 685
Hingtgen, J. N., 191
Holtzman, S. G., 185, 195, 633
Hong, J.-S., 801
Hooks, M. S., 467
Houdi, A. A., 843
Huang, J.-T., 909
Hudson, P. M., 801
Hughes, R. A., 49, 247
Huntzinger, J. A., 665

Ikarashi, Y., 921
Iqbal, M., 909

Jackson, D. M., 829
Jacquot, C., 775
Jibiki, I., 163
Johansson, P. E., 617
Johnson, M. P., 135, 345
Jolicoeur, F. B., 401, 463
Jones, D. N. C., 169
Jones, G. H., 467
Jones, L. F., 601
Josephy, M., 931
Justice, J. B., Jr., 467

Kalant, H., 427
Kanarek, R. B., 681
Katz, J. L., 411
Kauppila, T., 287
Kaushik, M., 665
Kautz, M. A., 85
Kavaliers, M., 485
Kelly, M. E., 147
Kelly, T. H., 417
Kemble, E. D., 759
Kemppainen, P., 287
Kent, S., 253
Kerenyi, S. Z., 527
Khanna, J. M., 427
Kimball, C. D., 909
Koryakina, L. A., 315
Kostrzewa, R. M., 215
Kow, L.-M., 359, 365
Kubota, T., 163
Kudryavtseva, N. N., 315
Kusanovic, R., 705

Langan, M. C., 433
Larsson, K., 201
Lau, C. E., 823
Laviola, G., 817
Lawrence, M. S., 869
Lee, J. D., 549
Lee, S.-F., 549
Leidenheimer, N. J., 99, 519
Lemaire, S., 401
Leong, F. W., 433
Leshem, M., 475
Levin, E. D., 243
Li, D., 685
Li, E. T. S., 495
Li, H., 253
Liau, L. M., 555
Liminga, U., 617
Lin, C.-H., 549
Lipton, J., 927
Liu, W.-F., 549, 747
Loggi, G., 817
Lorens, S. A., 223
Luck, K. A., 273
Luo, S., 495
Lutfy, K., 853

McConville, B. J., 875
McGee, M., 501
McKenna, D. J., 505
McMullan, D. M., 115
McNamara, R. K., 651
McNaughton, N., 43

Ma, C., 549
Mackenzie-Taylor, D., 29
Malatynska, E., 695
Mangum, K. A., 115
Markowska, A. L., 731
Marks-Kaufman, R., 681
Martin, B. R., 353
Martin, W. R., 561
Maruyama, Y., 921
Massi, M., 881
Massi, P., 569
Mastropaolo, J., 665
Matsuzaki, Y., 921
Matthies, H., 471
Mayer, D. J., 475
Megirian, D., 253
Meguro, K., 921
Meisch, R. A., 897
Menard, D., 401
Mench, J. A., 587
Middaugh, L. D., 763
Mignot, E., 1
Miller, D. B., 339
Miller, S., 527
Mintz, M., 327
Mitchell, C. L., 801
Mitsushio, H., 223
Molina, V. A., 125
Monaco, V., 889
Mora, S., 705
Morgat, J.-L., 155
Morgenstern, R., 321
Mos, J., 447
Mundy, W. R., 861
Muntaner, C., 411
Murphy, M. R., 527
Murua, V. S., 125
Murzi, E., 533
Myers, R. D., 379
Myslobodsky, M. S., 327

Nader, M. A., 611
Nanry, K., 861
Naylor, R. J., 147, 169
Neill, D. B., 467
Nichols, D. E., 135, 345, 581
Nicholson, D., 753
Nicolaïdis, S., 545
Njung'e, K., 63
Noda, Y., 441
Norman, A. B., 875
Novitzki, M. R., 665
Nowak, G., 691
Nowakowska, E., 265
Nyce, J. W., 379

Oberlender, R., 135, 581
O'Callaghan, J. P., 339
Ochi, Y., 441
O'Connor, D. A., 267
O'Connor, S., 1
Ojea, S. I., 739
Oka, M., 441
Olivier, B., 447
Olson, K. G., 219
Ong, J., 829
Orosco, M., 775
Ott, T., 321
Overstreet, D. H., 105
Owen, D. A. A., 147

Paez, X., 379
Pandey, U., 353
Papanek, P. E., 837
Parenti, M., 569
Paris, J. M., 223
Park, W. K., 191
Parker, L. A., 375
Parolaro, D., 569
Patrini, G., 569
Paul, I. A., 621
Paule, M. G., 77
Peck, J. A., 227, 501
Penetrante, M. L., 433
Perfumi, M., 881
Perkins, K. A., 715
Peroutka, S. J., 555
Perretta, G., 889
Pertovaara, A., 287
Pfaff, D. W., 359, 365
Pitha, J., 555
Pitsikas, N., 931
Polidori, C., 881
Pompei, P. L., 881
Pournaghash, S., 479
Powell, K. R., 621
Pradhan, S. N., 293, 699
Pruitt, T., 561

Radulovacki, M., 1
Ramsey, V. A., 659
Rawleigh, J. M., 759
Rech, R. H., 29
Redmond, E., Jr., 869
Reeber, C., 837
Reid, A., 753
Reite, M., 677
Rijnders, H. J., 769
Riley, A. L., 85, 267, 479
Ríos, C., 807
Rivest, R., 401, 463
Robert, J. J., 775
Rodefer, J., 715
Rogers, B. C., 861
Roques, B. P., 155, 545
Rose, J. E., 243, 333
Rosenberg, H. C., 659
Rouch, C., 775
Rubino, T., 569
Ruethrich, H.-L., 471
Ruiz-Gayo, M., 155

Saldívar, A., 371, 807
Samson, H. H., 575
Sanberg, P. R., 875
Sasaki, H., 921
Satinoff, E., 253
Sawynok, J., 753
Schanley, D. L., 433
Schechter, M. D., 7, 99, 519, 539
Schino, G., 889
Schipper, J., 447
Schneider, R., 471
Schnur, P., 711
Schou, J. S., 93
Schulze, G. E., 77
Sekizawa, K., 921
Shah, G., 427
Shanks, N., 69
Shea, M. M., 587
Shechtman, O., 837
Shih, J.-H., 549
Shimada, E., 441
Shofel, A., 309
Shreve, P. E., 385
Shulgin, A. T., 505
Sierra, V., 853
Sijbesma, H., 447
Simansky, K. J., 459
Skelton, R. W., 651
Slangen, J. L., 13, 299, 769
Sleight, A. J., 555
Sloan, J. W., 561
Smith, A. D., 467
Smith, G. P., 207
Spear, D. J., 411
Spruijt, B. M., 931
Starr, B. S., 259
Starr, M. S., 259
Steele, T. D., 345
St-Pierre, S., 463
Stumpf, W. E., 621
Sufka, K. J., 49, 247
Sutton, D., 909
Syapin, P. J., 639

Tackett, R. L., 601
Takishima, T., 921
Tanco, S. A., 273
Tandon, P., 861
Tang, M., 823
Tapia, C., 705
Tarrasch, R., 327
Teskey, G. C., 485
Tesserommatis, C., 813
Tietz, E. I., 659
Tilson, H. A., 861
Tolliver, G. A., 575
Tomkowiak, J. M., 253
Touzani, K., 37
Tripathi, H. L., 219
Tripp, G., 43
Troisi, A., 889
Trujillo, K. A., 673
Tsopanakis, C., 813
Turkkan, J. S., 55

Turndorf, H., 685
Tvede, K., 93
Tyers, M. B., 169
Tyrka, A., 207

Uretsky, N. J., 385

van Aken, H., 447
van Bergen, P., 837
Van De Poll, N. E., 795
Van Der Gugten, J., 13, 299
Vanderwolf, C. H., 689
Vander Zanden, J. M., 913
Van Loon, G. R., 843
Varrin, S. J., 917
Velley, L., 37

Wala, E. P., 561
Wall, T. L., 789
Wang, B. C., 685
Watkinson, W. P., 339
Wehner, J. M., 593
Weiner, I., 309
Weiner, J., 427
Wellman, P. J., 905
Wenk, G. L., 731
West, R., 281
Wetherington, C. L., 85
White, E. S., 681
Wilkins, J., 927
Wilson, L. M., 177
Wing, A. V., 211
Winter, E., 109
Wolffgramm, J., 389
Wong, L. S., 829
Woolley, D. E., 235
Wright, A., 147

Yamaguchi, N., 163
Yamamoto, M., 669, 921
Yanai, M., 921
Yatsugi, S., 669
Yim, G. K. W., 345
Yoburn, B. C., 853
Young, C. W., 633

Zacharko, R. M., 69
Zalcman, S., 69
Zanol, M. D., 875
Zeigler, S., 927
Zhang, L., 407